This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/pdb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/bindingdb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/pubchem-compound/
n22http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB04335/identifier/chebi/
n5http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB04335
rdf:type
n3:Drug
n3:description
A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)
n3:group
investigational
n3:indication
The primary popular claim made for inosine, that it enhances exercise and athletic performance, is refuted by the available research data. There is some preliminary evidence that inosine may have some neurorestorative, anti-inflammatory, immunomodulatory and cardioprotective effects.
owl:sameAs
n22:DB04335
dcterms:title
Inosine
adms:identifier
n10:17596 n11:5799 n12:22104 n13:D00054 n14:NOS n15:DB04335 n16:C00294 n17:3588 n18:Inosine n19:PA130230922 n20:6021
n3:mechanismOfAction
Inosine has been found to have potent axon-promoting effects in vivo following unilateral transection of the corticospinal tract of rats. The mechanism of this action is unclear. Possibilities include serving as an agonist of a nerve growth factor-activated protein kinase (N-Kinase), conversion to cyclic nucleotides that enable advancing nerve endings to overcome the inhibitory effects of myelin, stimulation of differentiation in rat sympathetic neurons, augmentation of nerve growth factor-induced neuritogenesis and promotion of the survival of astrocytes, among others. The mechanism of inosine's possible cardioprotective effect is similarly unclear. Inosine has been reported to have a positive inotropic effect and also to have mild coronary vasodilation activity. Exogenous inosine may contribute to the high-energy phosphate pool of cardiac muscle cells and favorably affect bioenergetics generally. Inosine has also been reported to enhance the myocardial uptake of carbohydrates relative to free fatty acids as well as glycolysis. In cell culture studies, inosine has been found to inhibit the production, in immunostimulated macrophages and spleen cells, of the proinflammatory cytokines, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, interleukin (IL)-12, macrophage-inflammatory protein-1 alpha and interferon (IFN)-gamma. It also suppressed proinflammatory cytokine production and mortality in a mouse endotoxemic model. These actions might account for the possible immunomodulatory, anti-inflammatory and anti-ischemic actions of inosine.
n3:synonym
Ribonosine Inosinum Inosina beta-Inosine Hypoxanthosine Oxiamin INO
n3:synthesisReference
U.S. Patent 3,049,536 U.S. Patent 3,111,459
foaf:page
n7:ino_0144.shtml
n3:IUPAC-Name
n8:271B50C7-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B50CD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B50CC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B50C9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B50CA-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B50CB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B50DD-363D-11E5-9242-09173F13E4C5 n8:271B50C5-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B50DF-363D-11E5-9242-09173F13E4C5 n8:271B50C3-363D-11E5-9242-09173F13E4C5 n8:271B50C6-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B50E0-363D-11E5-9242-09173F13E4C5 n8:271B50C4-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n5:S01XA10 n5:D06BB05 n5:G01AX02
n3:H-Bond-Acceptor-Count
n8:271B50D3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B50D4-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B50CE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B50CF-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B50D1-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B50D0-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B50D2-363D-11E5-9242-09173F13E4C5
n3:absorption
Ingested inosine is absorbed from the small intestine.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
58-63-9
n3:Bioavailability
n8:271B50D9-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B50DB-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B50DC-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B50DE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B50D8-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B50D7-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B50DA-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B50C8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B50D5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B50D6-363D-11E5-9242-09173F13E4C5